LABA/LAMA/ICS And LABA/ICS+LAMA Are In Medium Weight Comparison Of Curative Effect And Compliance In Stable COPD

Research objectives:1.To compare the clinical efficacy of Budesonide/Glycopyrronium Bromide/Formoterol Fumarate(BUD/GLY/FOR)and Budesonide/Formoterol Fumarate(B UD/FOR)combined with tiotropium bromide in stable patients with moderate t o severe chronic obstructive pulmonary disease(COPD).2.Patients’ compliance with BUD/GLY/FOR and(BUD/FOR)combined with tiotropium bromide were compared.Method: The patients with COPD who were hospitalized in the respirator y Department of the Affiliated Hospital of Yan ’an University for acute exacer bation from September 1,2021 to August 31,2022 were collected.After admi ssion,they were given appropriate treatments such as oxygen inhalation,anti-in fection,expectorant and asthmatic relief,etc.When the patients’ symptoms wer e stable,they were included in the study according to the sodium emission crit eria.Finally,a total of 120 patients with moderate to severe stable COPD wer e included.A total of 120 patients were divided into two groups according to a randomized,controlled trial design.60 patients were treated with Budesonide/Glycopyrronium Bromide/Formoterol Fumarate(160/7.2/4.8μg).Another 60 patien ts received Budesonide/Formoterol Fumarate powder aerosol(320μg / 9.0μg)+Tiotropium bromide powder aerosol(18.0μg)as control group.Pulmonary ventil ation function indexes,dyspnea grading(m MRC grading),COPD self-assessmen t test(CAT score),laboratory indexes(CRP,blood routine,blood coagulation),postoperative adverse reactions and times of drug purchase were compared bet ween the two groups at 3 and 6 months after treatment,respectively.Data of eligible patients were collected and included in the study,and the data were i mported into SPSS26.0 software for statistical analysis.By comparing the chan ges of various observation indicators before and after treatment in the two gro ups,the efficacy and compliance of the two different drug administration meth ods in patients with moderate and severe COPD were evaluated.Results:1.A total of 120 patients were included in this study.Statistical analysis was conducted on the m MRC grading,pulmonary ventilation function index and CAT score of patients in the two groups at 3 and 6 months of treatment.After treatment,all scores of patients in the two groups decreased and pulmonary ventilation index increased,with statistical significance(P< 0.05).Two different administration methods can improve the symptoms of patients and lung ventilation function;However,a comparison between the two groups after treatment showed that there was no significant difference in improving symptoms and lung function between the two groups(P > 0.05).2.Laboratory indicators: After 3 months and 6 months of treatment,the inflammatory indexes and hemagglutination indexes of the two groups were statistically analyzed,and the inflammatory indexes and hemagglutination indexes of the two groups were significantly decreased after treatment compared with that before treatment,the difference was statistically significant(P< 0.05).The two different administration modes could reduce the inflammatory response and improve the hypercoagulability of the patients with COPD.However,the comparison between the two groups after treatment showed that the inflammatory level and hemagglutination status of the two groups were basically the same,and the difference was not statistically significant(P > 0.05).The two drug administration methods had basically the same effect in improving the inflammatory response and blood hypercoagulability of COPD patients.3.Drug compliance: The comparison between the two groups after treatment showed that the compliance of patients in the observation group was better than that in the control group,and the difference was statistically significant(P< 0.05).4.Adverse reactions: After treatment,the number of patients in the two groups with hoarseness,headache,palpitation and oral candida infection were basically the same.Conclusion: Based on the findings of this study,for moderate to severe COPD patients,compared with Budesonide/Glycopyrronium Bromide/Formoterol Fumarate single inhaler triple therapy with Budesonide/Formoterol Fumarate + Tiotropium bromide multi-inhaler triple therapy,After 6 months of treatment,there were no significant differences between the two groups in improving symptoms,improving lung function,reducing inflammatory response,improving blood hypercoagulability and adverse reactions after drug treatment,but the compliance of Budesonide/Glycopyrronium Bromide/Formoterol Fumarate was better.